ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY)

51.59
-0.75
(-1.43%)
Closed March 18 04:00PM
51.95
0.36
( 0.70% )
Pre Market: 07:11AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
51.95
Bid
-
Ask
-
Volume
386
0.00 Day's Range 0.00
47.58 52 Week Range 71.065
Market Cap
Previous Close
51.59
Open
-
Last Trade
70
@
51.79
Last Trade Time
07:13:05
Financial Volume
-
VWAP
-
Average Volume (3m)
17,127,427
Shares Outstanding
2,022,193,411
Dividend Yield
4.50%
PE Ratio
13.00
Earnings Per Share (EPS)
3.97
Revenue
45.01B
Net Profit
8.03B

About Bristol Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bristol Myers Squibb Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker BMY. The last closing price for Bristol Myers Squibb was $51.59. Over the last year, Bristol Myers Squibb shares have traded in a share price range of $ 47.58 to $ 71.065.

Bristol Myers Squibb currently has 2,022,193,411 shares outstanding. The market capitalization of Bristol Myers Squibb is $104.32 billion. Bristol Myers Squibb has a price to earnings ratio (PE ratio) of 13.00.

BMY Latest News

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “SO, Have You Found It?” campaign. This initiative spotlights the resilience of ar...

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications Bristol Myers Squibb (NYSE: BMY) today annou...

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion b...

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024. Company executives will review financial results and address inquiries from investors ...

U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

In the Phase 3 CheckMate -901 trial, Opdivo with cisplatin and gemcitabine demonstrated a statistically significant improvement in overall survival and progression-free survival compared to cisplatin-...

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024. Samit Hirawat, M.D., executive vice president, chief medical offi...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.49-4.5738427626754.4455.03551.533941030552.46727471CS
42.064.1290839847749.8955.03549.5352022906352.16870283CS
12-0.46-0.87769509635652.4155.03547.581712742750.9382578CS
26-6.61-11.28756830658.5659.4647.581526562151.82918488CS
52-14.71-22.067206720766.6671.06547.581228220656.40905093CS
156-10.12-16.304172708262.0781.43547.581152514264.29838186CS
2601.943.8792241551750.0181.43541.191243065260.75766592CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FUSNFusion Pharmaceuticals Inc
$ 21.15
(98.78%)
796.87k
OTRKOntrak Inc
$ 0.325
(71.05%)
5.8M
ZCARZoomcar Holdings Inc
$ 1.77
(50.00%)
9.31M
BTCTBTC Digital Ltd
$ 3.87
(32.99%)
159
NCMINational CineMedia Inc
$ 5.60
(32.70%)
107.42k
GWAVGreenwave Technology Solutions Inc
$ 0.1682
(-54.91%)
538.35k
PIXYShiftPixy Inc
$ 4.50
(-33.82%)
305.39k
ACXPAcurx Pharmaceuticals Inc
$ 1.93
(-25.48%)
3
AFIBAcutus Medical Inc
$ 0.2141
(-18.28%)
357.36k
AIRJMontana Technologies Corporation
$ 9.06
(-18.08%)
86
ZCARZoomcar Holdings Inc
$ 1.77
(50.00%)
9.31M
OTRKOntrak Inc
$ 0.325
(71.05%)
5.8M
VERBVerb Technology Company Inc
$ 0.3765
(4.58%)
4.36M
SQQQProShares UltraPro Short QQQ
$ 11.22
(1.54%)
2.18M
ENVBEnveric Biosciences Inc
$ 1.37
(24.55%)
1.87M

BMY Discussion

View Posts
DewDiligence DewDiligence 8 months ago
AZN pays BMY/Ono Pharma $510M to_settle_all_patent_litigation_regarding Imjudo/Imfinzi:

https://www.fiercepharma.com/pharma/bristol-myers-astrazeneca-settle-pd-1-ctla-4-cancer-immunotherapy-patent-suits-510m
👍️0
DewDiligence DewDiligence 8 months ago
BMY 2Q23 CC transcript:

https://www.fool.com/earnings/call-transcripts/2023/07/27/bristol-myers-squibb-bmy-q2-2023-earnings-call-tra
👍️0
DewDiligence DewDiligence 8 months ago
BMY reports 2Q23 results—cuts 2023 non-GAAP EPS guidance:

PR:
https://s21.q4cdn.com/104148044/files/doc_financials/quarterly_reports/2023/BMY-Q22023-Earnings-Press-Release.pdf

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2023/BMY-2023-Q2-Results-Investor-Presentation-Appendix.pdf


2023 non-GAAP EPS guidance is now $7.35-7.65, down $0.60 from the prior range of $7.95-8.25. The new guidance represents a 4% YoY decline at the midpoint of the range. The reason for the cut is lower expected sales of Revlimid (now generic) and Pomalyst (soon to be generic).
👍️0
DewDiligence DewDiligence 8 months ago
Opdivo monotherapy—>statsig OS/PFS as_addend_to_cisplatin_in first-line bladder cancer:

https://finance.yahoo.com/news/opdivo-nivolumab-combination-cisplatin-based-105900450.html

The trial in question is a 600-patient sub-study of CHECKMATE-901, which is now complete. (The other part of CHECKMATE-901, which compares Opdivo/Yervoy vs chemo, is ongoing.) The trial had no requirement for PD-L1 expression.

Today’s PR does not contain a hazard ratio or any other detailed results; those data will be presented at an unspecified medical conference.

Opdivo for bladder cancer is already FDA-approved in the adjuvant (#msg-165546303) and second-line (#msg-128386168) settings. Approval in the first-line (unresectable or metastatic) setting would give Opdivo across-the-board coverage for bladder cancer.
👍️0
DewDiligence DewDiligence 8 months ago
BMY opts-in for worldwide rights_to PRTA’s anti-tau compound, PRX005:

https://www.businesswire.com/news/home/20230710599297/en

PRTA reported phase-1 data for PRX005 in Alzheimer’s disease in Jan 2023 (#msg-171085895).

BMY opted in for the US rights to PRX005 in 2021 (#msg-164573926), which resulted in an $80M milestone payment to PRTA. Today’s opt-in for the ex-US rights generates an additional $55M payment to PRTA.

This collaboration, which BMY inherited from CELG (#msg-139431013), potentially includes two drug candidates in addition to PRX005 (one targeting TDP-43 and one with an undisclosed target), but BMY has as yet opted in only for PRX005 and has shown no interest in the other two candidates, as far as I know.
👍️0
DewDiligence DewDiligence 9 months ago
GERN submits Imetelstat NDA for treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes:

https://www.businesswire.com/news/home/20230620336071/en

This is an indication where BMY is seeking FDA approval for Reblozyl and where Reblozyl is already approved in the EU.
👍️0
DewDiligence DewDiligence 9 months ago
BMY sues US government regarding IRA:

https://www.bms.com/impact-of-the-inflation-reduction-act-on-innovative-medicines-for-patients.html

The arguments are very similar to MRK’s IRA lawsuit (#msg-172068691). It seems pretty likely that these lawsuits will eventually be consolidated.
👍️0
DewDiligence DewDiligence 9 months ago
BMY’s ASCO slide set:

https://s21.q4cdn.com/104148044/files/doc_presentations/2023/bmy-asco-investor-presentation.pdf

These are the slides that accompanied BMY’s investor webcast today.
👍️0
DewDiligence DewDiligence 9 months ago
Opdivo bests Adcetris in first-line-HL PFS—immature_OS_data_trending_in_favor_of_Opdivo:

https://www.fiercepharma.com/pharma/seagens-top-selling-drug-under-threat-bristol-myers-opdivo-beats-adcetris-lymphoma Compared with Adcetris, Bristol Myers Squibb’s Opdivo significantly reduced the risk of cancer progression or death by 52% [i.e. the HR for PFS was 0.48—Dew] in adults and children with newly diagnosed stage 3 or 4 classical Hodgkin lymphoma, according to phase 3 data unveiled at the 2023 American Society of Clinical Oncology annual meeting. Both drugs were used on top of the AVD regimen of chemotherapy.

The collaborative group-conducted trial, coded SWOG S1826, randomized nearly 1,000 patients. The results point to Opdivo-AVD as “a new standard of care that is better tolerated and results in a higher proportion of patients with durable remissions” than Adcetris-AVD, Oreofe Odejide, M.D., from the Dana-Farber Cancer Institute and an invited ASCO expert, said in a statement.

…Opdivo is currently only allowed in HL following Adcetris treatment thanks to an FDA accelerated approval in 2016. The new SWOG trial will support an FDA filing for Opdivo in front-line treatment, Herrera told Fierce Pharma in an interview. It could also help Bristol Myers turn the original conditional nod into a full approval.

…The Opdivo regimen has yet to show a significant patient survival benefit. By the data cutoff, 11 (2.2%) deaths happened in the Adcetris arm, compared with four (0.8%) for Opdivo. It will take a few years for the OS data from this trial to reach maturity.
👍️0
DewDiligence DewDiligence 10 months ago
Repotrectinib NDA has 11/27/23 PDUFA date—(with FDA priority review):

https://finance.yahoo.com/news/u-food-drug-administration-accepts-105900511.html

The indication is locally advanced or metastatic ROS1-positive NSCLC.
👍️0
DewDiligence DewDiligence 10 months ago
CHMP approves Opdivo/chemo in neoadjuvant NSCLC:

https://www.businesswire.com/news/home/20230525005752/en
👍️0
DewDiligence DewDiligence 10 months ago
Milvexian—>FDA Fast Track designation for_all_indications:

https://finance.yahoo.com/news/milvexian-granted-u-fda-fast-105900364.html

The three indications BMY is pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF.
👍️0
DewDiligence DewDiligence 10 months ago
BMY’s BMS-986278 for IPF will advance to phase-3:

https://www.businesswire.com/news/home/20230519005266/en
👍️0
DewDiligence DewDiligence 10 months ago
IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.
👍️0
DewDiligence DewDiligence 10 months ago
BMY’s ASCO/EHA/ICML lineup:

https://www.businesswire.com/news/home/20230510006079/en
👍️0
DewDiligence DewDiligence 10 months ago
$3.4M insider sale yesterday by BMY’s CSO, Rupert Vessey:

https://www.sec.gov/Archives/edgar/data/14272/000001427223000114/xslF345X04/wf-form4_168323704827586.xml

Unless Vessey is buying a house, a sale of this size at this price level is somewhat concerning.
👍️0
DewDiligence DewDiligence 11 months ago
BMY 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-bristol-myers-squibb-042637576.html
👍️0
DewDiligence DewDiligence 11 months ago
BMY 1Q23 results…

PR:
https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2023/default.aspx

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2023/BMY-2023-Q1-Results-Presentation-Appendix.pdf

2023 non-GAAP EPS guidance remains $7.95-8.25, +4% YoY at the midpoint of the range.
👍️0
DewDiligence DewDiligence 11 months ago
BMY’s CCO, Christopher Boerner—>CEO effective 11/1/23:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000014272/000114036123020605/brhc20052030_8k.htm

CEO, Giovanni Caforio will become Executive Chairman on 11/1/23. Between now and 11/1/23, Boerner will have the title of COO.
👍️0
DewDiligence DewDiligence 11 months ago
CHMP approves Camzyos:

https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-184200509.html
👍️0
DewDiligence DewDiligence 12 months ago
CHMP approves Breyanzi in second-line LBCL:

https://www.businesswire.com/news/home/20230330005697/en

FDA approval in this indication came in Jun 2022 (#msg-169240243).
👍️0
DewDiligence DewDiligence 12 months ago
BMY, EVO extend/expand neurodegeneration collaboration:

https://www.accesswire.com/viewarticle.aspx?id=746175&lang=en

The collaboration now runs for another eight years, and EVO receives an additional $50M in up-front cash.

Note that BMY and EVO are also collaborating in protein degradation (#msg-168811996).
👍️0
DewDiligence DewDiligence 12 months ago
EC approves Sotyktu for psoriasis:

https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-105900011.html

Essentially same label as FDA’s.
👍️0
DewDiligence DewDiligence 1 year ago
TAK-279 vs Sotyktu (from biopharmadive.com): #msg-171480207.
👍️0
DewDiligence DewDiligence 1 year ago
BMY will not launch Opdualag in Germany due to pricing constraints on FDC (combination) drugs:

https://endpts.com/bristol-myers-axes-german-launch-of-new-cancer-drug-citing-pricing-hurdles/
👍️0
DewDiligence DewDiligence 1 year ago
BMY/JNJ unveil_phase-3_program_for Milvexian—50,000 patients_across_three_ trials_in secondary stoke prevention, ACS, and AF/primary stroke prevention:

https://www.businesswire.com/news/home/20230228006466/en Enrollment has begun for the Librexia STROKE trial, which is evaluating milvexian in addition to standard of care antiplatelet therapy for stroke prevention in patients after an acute ischemic stroke or high-risk transient ischemic attack. The Librexia ACS trial, which will evaluate event reduction in acute coronary syndromes in addition to standard of care antiplatelet therapy, and the Librexia AF trial, which will investigate milvexian compared to apixaban [Eliquis] in the prevention of stroke in patients with atrial fibrillation, will also initiate during the first half of 2023. Milvexian is an oral FXIa inhibitor. The phase-3 trial in secondary stroke prevention is at: https://www.clinicaltrials.gov/ct2/show/NCT05702034 .

The commercial impetus for the Milvexian program is to supersede Eliquis (BMY) and Xarelto (JNJ) when those drugs go off-patent or become subject to Medicare price-setting. The competition for Milvexian is Bayer’s Asundexian, another oral FXIa inhibitor that started a somewhat less aggressive phase-3 program (#msg-169841711) that does not have a trial for ACS.
👍️0
DewDiligence DewDiligence 1 year ago
Opdivo PDUFA date for adjuvant melanoma—>10/13/23:

https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900042.html

The corresponding MAA has been validated by the EMA, starting the review clock.

The sBLA and MAA are based on the CHECKMATE-076 study, which showed HR=0.42 for the primary RFS endpoint (#msg-170239823).
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s ACC lineup:

https://www.businesswire.com/news/home/20230224005299/en
👍️0
DewDiligence DewDiligence 1 year ago
BMY/TVST report Abecma data from phase-3 KarMMa-3 study:

https://www.businesswire.com/news/home/20230209005647/en At a median follow up of 18.6 months, treatment with Abecma (n=254) demonstrated a clinically meaningful and statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared with standard regimens (n=132), with a median PFS of 13.3 months (95% CI: 11.8-16.1) vs. 4.4 months (95% CI: 3.4-5.9), respectively (HR:0.49; p<0.0001).Abecnma is currently FDA-approved for fifth-line MM; the results above should enable a label expansion into the third-line setting.
👍️0
DewDiligence DewDiligence 1 year ago
BMY -2.5% today—possible reason is that the CEO just sold $18M worth of stock—approximately half his holding—(the Form-4 filing hit the wires last night after the close):

https://www.sec.gov/Archives/edgar/data/14272/000001427223000044/xslF345X03/wf-form4_167590496019590.xml

It's hard to interpret a transaction of this size as non-bearish. I wonder if Giovanni Caforio is planning to retire in the next 12-18 months.
👍️0
DewDiligence DewDiligence 1 year ago
Bayer enrolls first phase-3 patients for FXIa inhibitor, Asundexian:

https://www.businesswire.com/news/home/20230208005322/en
• The OCEANIC program will investigate the efficacy and safety of asundexian (BAY2433334) in the prevention of stroke in patients with atrial fibrillation and also patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA)
2
• OCEANIC-AF and OCEANIC-STROKE are expected to enroll more than 27,000 patients in over 40 countries Bayer’s competition in this arena is BMY/JNJ’s Milvexian (#msg-169818942, #msg-169841711), which is awaiting the start of phase-3.
👍️0
DewDiligence DewDiligence 1 year ago
BMY 4Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2023/02/02/bristol-myers-squibb-bmy-q4-2022-earnings-call-tra/
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s Sotyktu patients are coming approximately 1/3 from treatment-naïve, 1/3 for Otezla switches, and 1/3 from biologic switches. (Source: 4Q22 CC.)
👍️0
DewDiligence DewDiligence 1 year ago
BMY 4Q22 CC slides:

https://s21.q4cdn.com/104148044/files/doc_presentations/2022/BMY-Q4-2022-Results-Presentation-with-Appendix.pdf
👍️0
DewDiligence DewDiligence 1 year ago
BMY 4Q22 results—2023 guidance:

https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2022/default.aspx

2023 non-GAAP EPS guidance is $7.95-8.25; at the midpoint of the range, this is a 4% increase relative to 2022’s non-GAAP EPS of $7.70.
👍️0
DewDiligence DewDiligence 1 year ago
CHMP approves BMY’s Sotyktu for psoriasis:

https://www.businesswire.com/news/home/20230125005858/en
👍️0
DewDiligence DewDiligence 1 year ago
Addendum—Breyanzi is the first CAR-T to show efficacy in CLL, as far as I know. rrCLL is a large market; if Breyanzi’s complete-response rate after, say, 5 years is as high as 15-20%, this indication could be a meaningful commercial contributor.

Breyanzi, which is currently approved for various forms of relapsed NHL, has annualized sales of under $200M.
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s Breyanzi meets primary endpoint in rrCLL/SLL single-arm trial:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-transcend-115900140.html Bristol Myers Squibb today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Results from TRANSCEND CLL 004 showed the study met the primary endpoint of complete response rate compared to historical control in the prespecified subset of patients with R/R CLL that was refractory to a BTK inhibitor and pretreated with a BCL-2 inhibitor. The trial listing is at:
https://www.clinicaltrials.gov/ct2/show/NCT03331198
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s JPM webcast slides:

https://www.sec.gov/Archives/edgar/data/14272/000114036123000970/brhc10046308_99-1.htm
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s Breyanzi continues to show robust results in second-line LBCL after longer follow-up:

https://www.fiercepharma.com/pharma/bristol-myers-bolsters-breyanzis-earlier-lymphoma-case-elevated-car-t-fight-against-gilead-0

Data from the same trial presented one year ago (at ASH 2021) are in #msg-164317285.
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s ASH presentations:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-first-115900939.html
👍️0
DewDiligence DewDiligence 1 year ago
BMY boosts annualized dividend to $2.28—(from $2.16):

https://finance.yahoo.com/news/bristol-myers-squibb-announces-dividend-211600245.html

At the current share price ($79.88), the new annualized payout is a yield of 2.9%.
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s ASH lineup:

https://finance.yahoo.com/news/bristol-myers-squibb-data-ash-115900163.html
👍️0
DewDiligence DewDiligence 1 year ago
BMY’s AHA presentation lineup:

https://finance.yahoo.com/news/data-reinforcing-impact-bristol-myers-105900941.html
👍️0
DewDiligence DewDiligence 1 year ago
BMY scores phase-3 win for Reblozyl in a new MDS indication:

https://www.businesswire.com/news/home/20221029005019/en
👍️0
DewDiligence DewDiligence 1 year ago
BMY 3Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2022/10/26/bristol-myers-squibb-bmy-q3-2022-earnings-call-tra/
👍️0
DewDiligence DewDiligence 1 year ago
BMY 3Q22 CC slides:

https://s21.q4cdn.com/104148044/files/doc_presentations/2022/BMY-2022-Q3-Results-Investor-Presentation.pdf
👍️0
DewDiligence DewDiligence 1 year ago
BMY 3Q22 results—2022 non-GAAP guidance unchanged:

https://www.businesswire.com/news/home/20221026005143/en

Non-GAAP EPS guidance remains $7.44-7.74.

This PR wasn’t supposed to come out until Wednesday morning. (Somebody must have goofed.)
👍️0
DewDiligence DewDiligence 1 year ago
Camzyos sNDA for prevention of SRT* in patients with symptomatic obstructive HCM has 6/16/23 PDUFA date:

https://finance.yahoo.com/news/u-food-drug-administration-fda-105900322.html

*Septal Reduction Therapy, a surgical intervention to correct a structural heart defect.
👍️0
DewDiligence DewDiligence 1 year ago
BMY—Opdivo monotherapy—>RFS HR=0.42 in adjuvant melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-presents-data-203000448.html Bristol Myers Squibb today announced results from the Phase 3 CheckMate-76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB or IIC melanoma. At a pre-specified interim analysis, the trial met its primary endpoint of recurrence-free survival (RFS); Opdivo reduced the risk of recurrence or death by 58% versus placebo (hazard ratio [HR] 0.42; 95% CI 0.30-0.59; p < 0.0001). This trial was open to all comers regardless of PD-L1 status. The RFS HR of 0.42 is quite impressive and should lead to another approved indication for Opdivo in the adjuvant setting.

BMY announced the success of this trial on 9/15/22 (#msg-169956859), but the details were disclosed for the first time today.
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com